| Passive immunity and its clinical application in paediatric disease (DNB 2023/1)5 | 215 | 2023 |
| Outline the approach to management of a 2-month old infant having fever without focus (DNB 2009/1)10 | 220 | 2009 |
| Discuss definition, aetiology & approach to investigation of PUO (DNB 2007/1)10 | 222 | 2007 |
| Enumerate the common causes of pyrexia of unknown origin in a 5-year-old child. Discuss diagnostic approach to fever with rash (DNB 2011/2)4+6 | 222 | 2011 |
| Differential diagnosis of fever with rash in children (DNB 2020/2)5 | 222 | 2020 |
| Common differential diagnoses of fever with rash in a 5 year old child (DCH 2024/1)5 | 222 | 2024 |
| Nosocomial Infections (DNB 2006/1)10 | 224 | 2006 |
| Define the role and principles of Antibiotic stewardship in inpatient and outpatient settings in pediatric practice (DNB 2020/1)5+5 | 226 | 2020 |
| Antibiotic stewardship (DNB 2022/1)5 | 226 | 2022 |
| Strategies for minimizing antibiotic abuse in hospitalized children (DNB 2022/2)5 | 226 | 2022 |
| A) Pathogenesis of toxic shock syndrome (TSS) B) Diagnostic criteria for TSS C) Differential diagnosis and management of TSS (DNB 2015/1)3+2+2+3 | 227 | 2015 |
| Diagnosis and management of Staphylococcal Toxic shock syndrome (DNB 2017/2)5 | 227 | 2017 |
| Management of Acute Rheumatic Fever (DNB 1993/2)10 | 229 | 1993 |
| Criteria for diagnosis of Rheumatic fever (DNB 2022/2)5 | 229 | 2022 |
| Prophylaxis of Rheumatic fever (DNB 2022/2)5 | 229 | 2022 |
| Diagnostic criteria for rheumatic fever in children (DNB 2023/1)5 | 229 | 2023 |
| Complications of diphtheria (DNB 2018/2)6 | 233 | 2018 |
| Diphtheritic myocarditis (DNB 2019/2)5 | 233 | 2019 |
| Discuss briefly the differential diagnosis and management of a 3-year-old unimmunized child presenting with fever and stridor for 3 days (DNB 2020/1)5+5 | 233 | 2020 |
| Antitoxin Therapy in Diphtheria - Guidelines (DNB 2021/2)4 | 233 | 2021 |
| Pathogenesis and management of diphtheria (DNB 2023/2)5 | 233 | 2023 |
| Outline the treatment of a child with diphtheria. What are the complications of diphtheria? (DNB 2024/1)5 | 233 | 2024 |
| Discuss prevention and prophylaxis against meningococcal infection (DNB 2005)5+5 | 237 | 2005 |
| Prophylaxis of Meningococcemia (DNB 2006/1)10 | 237 | 2006 |
| Discuss the etiology, pathogenesis and prevention of pertussis in chidren. Write the differences in efficacy, duration of protection and adverse events between whole cell and acellular pertussis vaccine (DNB 2014/1)6+4 | 243 | 2014 |
| Complications of Pertussis (DNB 2015/2)3 | 243 | 2015 |
| Diagnosis and management of pertussis (DNB 2016/1)5 | 243 | 2016 |
| Management and complications of pertussis in infants (DNB 2021/1)5 | 243 | 2021 |
| Treatment of typhoid fever (DNB 1993/1)10 | 244 | 1993 |
| Nontyphoidal salmonellosis (DNB 1995/2)15 | 244 | 1995 |
| Management of typhoid fever (DNB 1995/2)15 | 244 | 1995 |
| Interpretation of Widal test in immunized children (DNB 1998/2)10 | 244 | 1998 |
| Define multidrug resistant (MDR) salmonella typhi (MDR - ST) and nalidixic acid resistant salmonella typhi (NARST). Discuss the mechanism of development of drug resistance for salmonella typhi (DNB 2008/1)10 | 244 | 2008 |
| Diagnosis of enteric fever (DNB 2023/1)5 | 244 | 2023 |
| Discuss the pathogenesis of E. coli diarrhea (DNB 1994/2)15 | 246 | 1994 |
| Classification of E coli and pathogenesis of Invasive Diarrhoea (DNB 1995/1)15 | 246 | 1995 |
| Management of Plague (DNB 1995/2)10 | 249 | 1995 |
| Failure in control of Tuberculosis (DNB 1993/1)15 | 261 | 1993 |
| Prevention and early detection of TB (DNB 1996/2)15 | 261 | 1996 |
| Short course chemotherapy for TB (DNB 1998/2)10 | 261 | 1998 |
| DOTS chemotherapeutic management of Tuberculosis in National TB Control Programme (DNB 2000/1)15 | 261 | 2000 |
| Diagnosis and management of a child with resistant TB (DNB 2002/1)15 | 261 | 2002 |
| CNS changes in Tubercular meningitis (Pathological only) (DNB 2003/1)15 | 261 | 2003 |
| Discuss the pathogenesis, clinical symptomatology and diagnosis of NeuroTB (DNB 2006/1)10 | 261 | 2006 |
| How do you perform and interpret Mantoux Test. Enumerate 3 conditions each in which you can get a false positive and a false negative result (DNB 2006/1)10 | 261 | 2006 |
| Newer diagnostic modalities for TB (DNB 2006/2)10 | 261 | 2006 |
| DOTS regimen and the problems involved in the implementation in childhood TB (DNB 2006/2)10 | 261 | 2006 |
| What were the problems encountered in NTCP. Write the goals, strategies and essential components of RNTPC. Also discuss in brief categorization of patients and treatment protocols under RNTCP (DNB 2007/2)10 | 261 | 2007 |
| a) Describe the category based treatment in childhood TB b) Describe the pros and cons of intermittent therapy for tuberculosis c) What are the components of DOTS strategy as defined by WHO? (DNB 2009/2)3+3+4 | 261 | 2009 |
| Describe clinical manifestations, diagnosis and management of Neurotuberculosis (DNB 2011/2)3+4+3 | 261 | 2011 |
| Describe the flow chart for diagnosis of childhood tuberculosis under RNTCP. Write Briefly on DOT PLUS program (DNB 2012/1)6+4 | 261 | 2012 |
| Discuss the recent guidelines for diagnosis and management of childhood tuberculosis (DNB 2013/1)10 | 261 | 2013 |
| Describe aetiopathogenesis, diagnosis and management of different types of neurotuberculosis (DNB 2013/2)3+4+3 | 261 | 2013 |
| Clinical presentation, investigations and treatment of multidrug resistant TB (DNB 2014/2)3+2+5 | 261 | 2014 |
| a) Define DOTS, DOTS agents and DOTS plus b) List at least 4 important components of DOTS c) Give the categorization of treatment strategy in DOTS (DNB 2015/1)3+2+5 | 261 | 2015 |
| MDR and XDR tuberculosis treatment strategies (DNB 2016/1)3+3 | 261 | 2016 |
| Investigations for confirming diagnosis in tuberculous meningitis (DNB 2018/1)5 | 261 | 2018 |
| Recent advances in diagnosis of tuberculosis (DNB 2018/2)5 | 261 | 2018 |
| RNTCP program (DNB 2018/2)5 | 261 | 2018 |
| Principles of newer diagnostic tests in TB (DNB 2019/2)5 | 261 | 2019 |
| Role of CBNAAT (DNB 2019/1)5 | 261 | 2019 |
| MDR TB - Diagnosis and management (DNB 2021/2)6 | 261 | 2021 |
| Interpretation of Mantoux test (DNB 2022/2)5 | 261 | 2022 |
| Nucleic Acid Amplification Tests (NAAT) (DNB 2023/1)5 | 261 | 2023 |
| Fixed Drugs Combination of antitubercular drugs under National Tuberculosis Elimination Programme (DNB 2023/1)5 | 261 | 2023 |
| Laboratory diagnosis for pulmonary tuberculosis (DNB 2024/1)5 | 261 | 2024 |
| Current guidelines on tuberculosis preventive treatment (DNB 2024/1)5 | 261 | 2024 |
| Recent changes in treatment of Pediatric tuberculosis under NTEP (DNB 2024/1)5 | 261 | 2024 |
| Role of Rifamycins in tuberculosis (DNB 2024/1)5 | 261 | 2024 |
| Treatment of drug resistant tuberculosis (DNB 2024/2)6 | 261 | 2024 |
| Radiological features and conrmatory laboratory tests for congenital syphilis (DNB 2007/1)10 | 264 | 2007 |
| Management of a neonate born to VDRL positive mother (DNB 2023/1)5 | 264 | 2023 |
| Diagnosis and treatment of leptospirosis (DNB 2017/2)5 | 266 | 2017 |
| Clinical presentation and diagnosis of mycoplasma pneumonia infection (DNB 2016/2)5 | 269 | 2016 |
| Diagnosis and treatment of Scrub Typhus (DNB 2018/1)5 | 275 | 2018 |
| Laboratory findings and diagnosis of rickettsial infection (DNB 2018/2)5 | 275 | 2018 |
| Ricketssial infection- when to suspect (DNB 2019/2)5 | 275 | 2019 |
| Laboratory diagnosis and treatment of Scrub typhus (DNB 2024/1)5 | 275 | 2024 |
| Scrub typhus: a) Clinical features b) Diagnosis c) Investigation d) Treatment (DCH 2024/2)2+2+2+4 | 275 | 2024 |
| Enumerate invasive fungal diseases and its risk factors (DCH 2023/2)5 | 279 | 2023 |
| Invasive fungal diseases management - Pharmacotherapy (DCH 2023/2)5 | 279 | 2023 |
| Diagnosis and treatment of SSPE (DNB 1995/2)10 | 293 | 1995 |
| Diagnosis and prevention of Congenital Rubella Syndrome (DNB 2017/2)5 | 294 | 2017 |
| Pulse Polio Immunization (DNB 1996/1)15 | 296 | 1996 |
| Pulse Polio programme (DNB 1998/1)15 | 296 | 1998 |
| AFP Surveillance (DNB 1999/2)15 | 296 | 1999 |
| Approach to a child with AFP and components of AFP surveillance (DNB 2000/1)15 | 296 | 2000 |
| Pulse Polio programme (DNB 2001/1)15 | 296 | 2001 |
| AFP- Definition, Differential Diagnosis in details, how help in polio eradication (DNB 2003/2)15 | 296 | 2003 |
| Discuss the differential diagnosis and management of acute accid paralysis in a 2-year-old child (DNB 2004/2)5+5 | 296 | 2004 |
| What is AFP? Discuss the differential diagnosis and management of a child with AFP. Discuss AFP surveillance (DNB 2005/1)2+3+2+3 | 296 | 2005 |
| Define criteria for declaring a country Polio free. What is the present status of wild polio virus transmission and strategies being used for its control in India? Elaborate on AFP surveillance (DNB 2006/1)5+5 | 296 | 2006 |
| Define AFP. Enlist the causes and investigations of a case of AFP (DNB 2006/1)10 | 296 | 2006 |
| What is acute flaccid paralysis? Describe the differential diagnosis and management of a child with flaccid paralysis. Describe AFP surveillance (DNB 2009/2)2+2+4+2 | 296 | 2009 |
| a) Define polio eradication b) Polio eradication in india. c) Immunisation issues following polio eradication (DNB 2015/1)1+2+3 | 296 | 2015 |
| Discuss differential diagnosis of acute flaccid paralysis in tabular format (DNB 2021/1)5 | 296 | 2021 |
| Acute Flaccid Paralysis surveillance (DNB 2022/1)5 | 296 | 2022 |
| Enumerate causes of acute flaccid paralysis (AFP) (DNB 2023/2)5 | 296 | 2023 |
| Acute flaccid paralysis: a) Etiology b) Laboratory evaluation c) Management (DCH 2024/2)3+3+4 | 296 | 2024 |
| Risk factors and clinical features of Hand-Foot-Mouth disease (DNB 2022/2)5 | 297 | 2022 |
| Management of a child with Herpes simplex virus (HSV) encephalitis (DNB 2022/2)5 | 299 | 2022 |
| Management of chickenpox in an adolescent (DNB 2021/1)5 | 300 | 2021 |
| Roseola infantum (DNB 2015/2)3 | 303 | 2015 |
| Comment on clinical features, diagnosis and treatment of Swine u in children (DNB 2009/2)2+3+5 | 305 | 2009 |
| a) Virology and epidemiology of Swine Flu b) How is the disease categorized according to the government of India guidelines? c) Mention which children need to be immunized and who need to be given medication for the disease (DNB 2016/1+2+3+2+2) | 305 | 2016 |
| Current guidelines for management of H1N1 infection (DNB 2017/1)5 | 305 | 2017 |
| H1N1 infection-clinical features and management in children (DNB 2018/2)5 | 305 | 2018 |
| Prevalence, clinical manifestations and management of Covid-19 infections in children (DNB 2020/1)2+3+5 | 311 | 2020 |
| Prevention of COVID-19 infection (DNB 2020/2)5 | 311 | 2020 |
| Pediatric multisystem inflammatory syndrome (DNB 2020/2)5 | 311 | 2020 |
| Classification and treatment of Multisystem Inflammatory Syndrome in Children (DNB 2021/1)5 | 311 | 2021 |
| Psychosocial effects of COVID -19 on children (DNB 2021/1)5 | 311 | 2021 |
| Neonate born to COVID positive mother - Approach (DNB 2021/2)5 | 311 | 2021 |
| Paediatric COVID - Classification and management (DNB 2021/2)6 | 311 | 2021 |
| Tabulate the differences in clinical and laboratory features of Kawasaki disease and MIS-C (DNB 2022/2)5 | 311 | 2022 |
| Describe multiple inflammatory syndrome in children (DNB 2023/1)5 | 311 | 2023 |
| Epidemiology, clinical features, prognosis and prevention of Japanese Encephalitis (DNB 2015/1)2+3+2+3 | 314 | 2015 |
| Clinical features and treatment of Chikungunya (DNB 2016/2)5 | 314 | 2016 |
| Discuss the management of Dengue Shock Syndrome (DNB 1997/1)10 | 315 | 1997 |
| Pathogenesis of bleeding and shock in Dengue fever (DNB 1998/2)10 | 315 | 1998 |
| Dengue Fever (DNB 2003/2)15 | 315 | 2003 |
| Define DHF and DSS and outline the treatment of DSS (DNB 2005/1)10 | 315 | 2005 |
| Diagnosis and management of DHF and DSS (DNB 2006/1)10 | 315 | 2006 |
| Outline the WHO criteria for diagnosis of dengue hemorrhagic fever. Draw an algorithm for volume replacement for a child with DHF and >20% increase in hematocrit (DNB 2009/1)3+7 | 315 | 2009 |
| Define DHF and DSS. How does DHF differ from dengue fever with hemorrhage? Describe treatment of DSS (DNB 2009/2)2+2+1+5 | 315 | 2009 |
| Classify severity of dengue hemorrhagic fever. Write in brief the management of dengue shock syndrome (DNB 2011/1)4+6 | 315 | 2011 |
| What are the fluid, metabolic and biochemical changes in a child with severe dengue? Discuss the underlying pathophysiology (DNB 2013/1)10 | 315 | 2013 |
| Define severe dengue and describe the WHO guidelines for its management. Enumerate the indications for transfusion in dengue (DNB 2014/1)2+6+2 | 315 | 2014 |
| Define severe dengue. Describe the WHO guidelines for its management. Enumerate complications of Severe Dengue (DNB 2016/1)2+4+4 | 315 | 2016 |
| Definition and treatment of Dengue Hemorrhagic fever (DNB 2016/1)3 | 315 | 2016 |
| Diagnostic lab tests for dengue fever (DNB 2018/1)4 | 315 | 2018 |
| Fluid therapy in DHF (DNB 2019/1)5 | 315 | 2019 |
| Fluid management in Dengue Shock Syndrome and its complications (DNB 2019/2)5 | 315 | 2019 |
| Pathophysiology of Dengue fever (DNB 2021/2)5 | 315 | 2021 |
| Classification of dengue fever (DNB 2022/2)5 | 315 | 2022 |
| Management of Dengue Shock Syndrome (DNB 2022/2)5 | 315 | 2022 |
| Dengue and its classification (DCH 2023/2)5 | 315 | 2023 |
| Severe dengue management in 15 kg child (DCH 2023/2)5 | 315 | 2023 |
| Management of a 10-year-child with dengue shock (DNB 2024/1)5 | 315 | 2024 |
| Management of Dengue Shock Syndrome (DCH 2024/1)5 | 315 | 2024 |
| Describe the etiology, mode of transmission, clinical features and management of viral hemorrhagic fever in children (DNB 2012/1)2+2+3+3 | 317 | 2012 |
| Infants of HIV seropositive mothers (DNB 1995/1)15 | 322 | 1995 |
| HIV and Pediatrics (DNB 1998/2)10 | 322 | 1998 |
| Prevention of HIV infection during childhood (DNB 2002/1)15 | 322 | 2002 |
| Post exposure HIV prophylaxis (DNB 2003/2)15 | 322 | 2003 |
| An HIV positive mother has been admitted in labour. What will you do to prevent transmission of infection to the baby (DNB 2005/1)10 | 322 | 2005 |
| Factors involved in perinatal transmission of HIV infection and the various preventive measures (DNB 2006/1)10 | 322 | 2006 |
| Clinical Presentations requiring screening for HIV (DNB 2007/1)5 | 322 | 2007 |
| HIV and TB (DNB 2007/1)5 | 322 | 2007 |
| Prevention of Childhood AIDS (DNB 2007/2)10 | 322 | 2007 |
| Discuss the risk factors for vertical transmission of HIV infection and methods to prevent parent to child transmission of HIV (DNB 2009/1)4+6 | 322 | 2009 |
| Outline clinical and immunological criteria for starting anti-retroviral treatment (ART) in a HIV infected child. How will you monitor a child initiated on ART? (DNB 2009/2)6+4 | 322 | 2009 |
| Enlist the common opportunistic infections in HIV infected children. Describe the clinical features, diagnosis and management of herpes simplex infection in HIV infected children (DNB 2011/2)3+2+2+3 | 322 | 2011 |
| Discuss the available strategies for prevention of mother to child transmission of HIV (DNB 2012/1)10 | 322 | 2012 |
| Enumerate opportunistic infections in HIV infected children. How will you treat and prevent pneumocystis jiroveci infection? (DNB 2012/1)5+3+2 | 322 | 2012 |
| Briefly discuss the pulmonary disorders seen in children with HIV/AIDS (DNB 2013/1)10 | 322 | 2013 |
| Discuss the key issues in the management of an HIV exposed infant (DNB 2013/2)10 | 322 | 2013 |
| AIDS defining diseases in children (DNB 2016/2) | 322 | 2016 |
| Strategies to prevent mother to child transmission of HIV infection (DNB 2017/1) 5 | 322 | 2017 |
| Treatment guidelines of neonate born to HIV positive mother (DNB 2018/2)5 | 322 | 2018 |
| WHO guidelines for breastfeeding in a baby born to HIV positive mother (DNB 2019/1)5 | 322 | 2019 |
| Anti-retroviral therapy in children (DNB 2019/1)5 | 322 | 2019 |
| Dry blood PCR for HIV/AIDS testing (DNB 2019/1)5 | 322 | 2019 |
| Neonatal HIV - Modalities of management (DNB 2021/2)5 | 322 | 2021 |
| Prevention of mother to child transmission of HIV infection (DCH 2024/1)5 | 322 | 2024 |
| Role of cryptosporidium in causation of childhood diarrhea (DNB 2021/01)5 | 329 | 2021 |
| Current therapy of Kala azar (DNB 2017/2)5 | 331 | 2017 |
| Define drug resistant malaria, what are the different types of drug resistance as per WHO criteria. Discuss the various management strategies of Drug resistant Malaria (DNB 1993/1)15 | 334 | 1993 |
| Management of Cerebral Malaria (DNB 1993/2)15 | 334 | 1993 |
| Malaria prophylaxis (DNB 1994/2)15 | 334 | 1994 |
| Drug resistant Malaria (DNB 2003/1)15 | 334 | 2003 |
| What are management guidelines of malaria under the national programme? How will you manage a case of cerebral malaria (DNB 2004/2)4+6 | 334 | 2004 |
| Enumerate manifestations of Severe Malaria and their management (DNB 2006/2)10 | 334 | 2006 |
| A 4-year-old girl presents with history of fever for 2 days associated with severe anemia, black colored urine and splenomegaly. Discuss the management of this patient (DNB 2008/2)10 | 334 | 2008 |
| Describe clinical manifestations of cerebral malaria. Enlist the differential diagnosis and investigations required. Write management of a case of cerebral malaria in high endemic area (DNB 2009/1)(2+3+5) | 334 | 2009 |
| Define complicated malaria. Describe the management strategies of complicated malaria (DNB 2009/2)3+7 | 334 | 2009 |
| Provide algorithms for case-detection and treatment for a child with fever, suspected to have malaria, as per National Vector Borne Disease Control Program (DNB 2010/2)5+5 | 334 | 2010 |
| Write short notes on: Laboratory diagnosis of malaria (DNB 2011/2)5 | 334 | 2011 |
| List the WHO criteria to diagnose severe malaria. Discuss the management of a child with cerebral malaria (DNB 2013/1)4+6 | 334 | 2013 |
| Newer antimalarial drugs (DNB 2015/1)4 | 334 | 2015 |
| Clinical features, diagnostic tests and management of severe malaria in children (DNB 2017/1)10 | 334 | 2017 |
| Treatment of diagnosed cases of cerebral malaria (DNB 2018/1)5 | 334 | 2018 |
| Recent National malarial treatment guidelines (DNB 2019/1)5 | 334 | 2019 |
| Complications of severe falciparum malaria (DNB 2020/2)5 | 334 | 2020 |
| Management of severe malaria (DCH 2024/1)5 | 334 | 2024 |
| Life cycle of Ascaris lumbricoides (DNB 2022/2)5 | 337 | 2022 |
| Management of worm infestation in children (DNB 2017/1)5 | 339 | 2017 |
| Current management of Neurocysticercosis (DNB 1992/1)15 | 349 | 1992 |
| Brain CT findings in a case of Congenital toxoplasmosis and cysticercosis (DNB 1994/1)15 | 349 | 1994 |
| Management of neurocysticercosis (DNB 2016/2)3 | 349 | 2016 |
| Treatment of Hydatid cyst in children (DNB 2022/2)5 | 350 | 2022 |
| Adverse Events Following Immunisation (AEFI) (DNB 2025/1)5 | 215 | 2025 |
| Healthcare-associated infections (DNB 2025/1)5 | 224 | 2025 |
| Treatment of drug resistant tuberculosis (DNB 2024/2)5 | 261 | 2024 |
| Varicella Zoster Immunoglobulin (VZIG) (DNB 2025/1)5 | 300 | 2025 |
| Yellow fever vaccine in children (DNB 2025/1)5 | 316 | 2025 |
| Immune reconstitution inflammatory syndrome (IRIS) (DNB 2024/2)5 | 322 | 2024 |
| Rapid malaria antigen test (DNB 2025/1)5 | 334 | 2025 |
| Management of neurocysticercosis in children (DNB 2025/1)5 | 349 | 2025 |